Reported 896,867 shares, down 525,411 (36.9%) from the prior quarter.
Reported value -52.1%; share count -36.9% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-12-31 | 2179000 |
| 2022-03-31 | 11805000 |
| 2022-06-30 | 5650000 |
| 2022-09-30 | 3702000 |
| 2022-12-31 | 978194 |
| 2023-03-31 | 65831 |
| 2023-06-30 | 42724 |
| 2023-09-30 | 8997 |
| 2023-12-31 | 3101 |
| 2024-03-31 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q1 2024 | Reduced | 0 | -13,812 (-100.0%) | 0 | $0 | 2024-05-15 | |
| Q4 2023 | Reduced | 13,812 | -15,684 (-53.2%) | < 0.01% | $3,101 | 2024-02-13 | |
| Q3 2023 | Reduced | 29,496 | -31,192 (-51.4%) | < 0.01% | $8,997 | 2023-11-15 | |
| Q2 2023 | Reduced | 60,688 | -12,711 (-17.3%) | < 0.01% | $42,724 | 2023-08-14 | |
| Q1 2023 | Reduced | 73,399 | -755,578 (-91.1%) | < 0.01% | $65,831 | 2023-05-15 | |
| Q4 2022 | Added | 828,977 | +337,191 (68.6%) | < 0.01% | $978,194 | 2023-02-14 | |
| Q3 2022 | Reduced | 491,786 | -405,081 (-45.2%) | < 0.01% | $3,702,000 | 2022-11-14 | |
| Q2 2022 | Reduced | 896,867 | -525,411 (-36.9%) | < 0.01% | $5,650,000 | 2022-08-15 | |
| Q1 2022 | Added | 1,422,278 | +1,002,479 (238.8%) | < 0.01% | $11,805,000 | 2022-05-13 | |
| Q4 2021 | Added | 419,799 | +310,725 (284.9%) | < 0.01% | $2,179,000 | 2022-02-14 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
104 managers reported EIGER BIOPHARMACEUTICALS INC C for Q2 2022.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| AMERIPRISE FINANCIAL INC | Added | 7,675,577 | +180,514 | 0.02% | $48,356,000 | 8 qtrs |
| 683 Capital Management LLC | Added | 3,865,000 | +490,000 | 1.72% | $24,350,000 | 18 qtrs |
| BlackRock Inc | Added | 2,756,733 | +312,469 | < 0.01% | $17,367,000 | 25 qtrs |
| VANGUARD GROUP INC | Added | 1,919,336 | +230,093 | < 0.01% | $12,092,000 | 26 qtrs |
| ADAGE CAPITAL PARTNERS GP L L C | Reduced | 1,050,000 | -650,000 | 0.02% | $6,615,000 | 2 qtrs |
| MORGAN STANLEY This report | Reduced | 896,867 | -525,411 | < 0.01% | $5,650,000 | 26 qtrs |
| Soleus Capital Management L P | Added | 846,000 | +63,000 | 0.83% | $5,330,000 | 11 qtrs |
| STATE STREET CORPORATION | Added | 702,350 | +148,035 | < 0.01% | $4,425,000 | 14 qtrs |
| Knoll Capital Management LLC | Unchanged | 694,232 | 0 | 2.5% | $4,374,000 | 18 qtrs |
| GEODE CAPITAL MANAGEMENT LLC | Added | 691,469 | +55,898 | < 0.01% | $4,356,000 | 25 qtrs |
Filing details and methodology As reported
- Report period
- June 30, 2022
- Filed
- August 15, 2022
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 893,135
- Shared
- 0
- None
- 3,732
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.